Safety and efficacy of combination of oral iron chelators in thalassemia major patients

Justin Thomas; Pramod Sharma; Manish Parakh; Deepshikha Mandloi

doi:10.18203/2349-3291.ijcp20230734

Authors

Justin Thomas Department of Neurosciences, Pacific Medical College, Udaipur, Rajasthan, India
Pramod Sharma Department of Pediatric Medicine, Dr SN Medical College, Jodhpur, Rajasthan, India
Manish Parakh Department of Pediatric Medicine, Dr SN Medical College, Jodhpur, Rajasthan, India
Deepshikha Mandloi Department of Pediatrics, Lourdes Hospital, Kochi, Kerala, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20230734

Keywords:

Thalassemia major, Chronic iron overload, Iron chelators, Ferritin

Abstract

Background: To assess the safety and efficacy of combination of oral iron chelation therapy in transfusion dependent thalassemia patients and to compare it with other regimes.

Method: 150 transfusion dependent thalassemia patients with iron overload were recruited for a prospective, case control study. They were divided into 4 groups based on their chelation regime. The drugs used were deferasirox (DFX) alone, deferiprone (DFP) alone, DFP+DFX in combination, parenteral desferrioxamine (DFO) with either DFX or DFP with 50, 15, 70 and 15 in each group respectively. Doses used were DFX-30 mg/kg, DFP- 75 mg/kg/day, DFP+DFX-50 +30 mg/kg/day, DFO+DFP-25 mg/kg/d+50 mg/kg/day and DFO+DFX-25 mg/kg/d +30 mg/kg/d daily. Base line haematological, hepatic and renal profile and S. ferritin samples were collected and analyzed. Patients were monitored monthly for compliance and side effects. 30 patients were excluded during the course of study. Tests were repeated after 18 months period and the results of 120 patients were compared between the groups and statistically analyzed.

Results: There was statistically significant reduction of S. ferritin in both groups taking oral combination therapy and parenteral therapy (p<0.0001). There were no serious hematological, renal/hepatic side effects in any groups.

Conclusions: The oral combination therapy of iron chelators is safer and was well tolerated by all the patients and is similarly efficacious to the parenteral therapy in lowering S. ferritin.

Metrics

Metrics Loading ...

References

Whipple CH, Bradford WL. Mediterranean disease-thalassemia (erythroblastic anemia of Cooley); associated pigment abnormalities simulating hemochromatosis. J Pediat. 1936;9:279-311.

Mishra AK, Tiwari A. Iron overload in Beta thalassaemia major and intermedia patients. Maedica (Bucur). 2013;8(4):328-32.

Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR: Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104:34 39.

Brittenham GM, Cohen AR. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42:81-5.

Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of Deferasirox and Deferiprone in a patient with thalassaemia major and persisting severe iron overload after single agent chelation therapies. Blackwell Publishing Ltd, Br J Hematol. 2011;154:654-65.

Berdoukas V, Carson S, Nord A, Hofstra T, Claster S, Wood J, Coates TD. Combination of Two Orally Active Iron Chelating Agents: Efficacy and Safety In a Clinical Setting. Am Society Hematol Annual Meeting Exposition. 2011;10-13.

Chowdhury P, Chowdhury D, Chaudhury N. Safety and efficacy of sequential oral iron chelation therapy in transfusion induced siderosis in thalassemia syndrome. EGM Iron summit at Newdelhi, India. 2013.

Alavi S, Sadeghi E, Ashenagar A. Efficacy and safety of combined oral iron chelation therapy with Deferasirox and Deferiprone in a patient with beta-thalassemia major and persistent iron overload. Blood Res. 2014;49:65-73.

Elalfy MS, Wali Y, Tony S. Comparison of two combination iron chelation regimens, Deferiprone and Deferasirox versus Deferiprone and deferoxamine, in pediatric patients with thalassemia major. Blood. 2013;122:559.

Song TS, Hsieh YW, Peng CT, Chen TL, Lee HZ, Chung JZ, Hour MJ. Combined Versus Monotherapy OR Concurrent Therapy FOR Treatment of Thalassaemia. In Vivo. 2014;28(4):645-64.

Farmaki K, Tzoumari I, Pappa C, Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis. 2011;47(1):33-40.

Karami H, Kosaryan M, Amree AH, Darvishi-Khezri H, Mousavi M. Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major. Clin Pract. 2017;7(1):912.

Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study. Pediatr Blood Cancer. 2015;62(9):1592-6.

Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol. 2011;154:654-6.

Gomber S, Jain P, Sharma S. Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia. Indian Pediatr. 2016;53:207-10.